STOCK TITAN

Dimensional Fund Advisors (CSTL) discloses 3.9% passive stake in Castle Biosciences

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Dimensional Fund Advisors LP filed an amended Schedule 13G reporting passive ownership of common stock of Castle Biosciences Inc. Dimensional reports beneficial ownership of 1,143,799 shares, representing 3.9% of Castle Biosciences’ common stock as of the event date. It has sole voting power over 1,117,422 shares and sole dispositive power over 1,143,799 shares.

The filing explains that these shares are owned by various funds and accounts for which Dimensional or its subsidiaries act as investment adviser or manager. Dimensional states that it may be deemed a beneficial owner for Section 13(d) purposes but disclaims beneficial ownership of the securities, which are held by the underlying funds. The filing also certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Castle Biosciences.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Dimensional Fund Advisors LP
Signature:Selwyn Notelovitz
Name/Title:Global Chief Compliance Officer
Date:01/21/2026

FAQ

What percentage of Castle Biosciences (CSTL) does Dimensional Fund Advisors LP report owning?

Dimensional Fund Advisors LP reports beneficial ownership of 3.9% of Castle Biosciences Inc’s common stock, based on 1,143,799 shares.

How many Castle Biosciences (CSTL) shares does Dimensional Fund Advisors LP report on its Schedule 13G/A?

Dimensional Fund Advisors LP reports beneficial ownership of 1,143,799 shares of Castle Biosciences Inc common stock, with sole voting power over 1,117,422 shares.

Is Dimensional Fund Advisors LP’s stake in Castle Biosciences (CSTL) reported as passive?

Yes. Dimensional certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Castle Biosciences.

Who is the named reporting person on the Castle Biosciences (CSTL) Schedule 13G/A?

The reporting person is Dimensional Fund Advisors LP, a Delaware limited partnership and registered investment adviser.

Does Dimensional Fund Advisors LP claim full beneficial ownership of its Castle Biosciences (CSTL) position?

No. The filing explains that all reported securities are owned by underlying Funds, and Dimensional disclaims beneficial ownership of those securities beyond Section 13(d) purposes.

Who ultimately holds the right to dividends and sale proceeds for the Castle Biosciences (CSTL) shares?

According to the filing, the Funds advised or managed by Dimensional have the right to receive dividends and sale proceeds for the securities held in their respective accounts.
Castle Biosciences

NASDAQ:CSTL

CSTL Rankings

CSTL Latest News

CSTL Latest SEC Filings

CSTL Stock Data

1.17B
27.89M
2.9%
93.07%
5.23%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD